Relationship between endothelin-1 extraction in the peripheral circulation and systemic vascular resistance in patients with severe congestive heart failure

Journal of the American College of Cardiology

Volumn 33, Issue 2, 1999, Pages 530-537

  Tsutamoto, Takayoshi ^a   Wada, Atsuyuki ^a   Hisanaga, Tomoko ^a   Maeda, Keiko ^a   Ohnishi, Masato ^a   Mabuchi, Naoko ^a   Sawaki, Masahide ^a   Hayashi, Masaru ^a   Fujii, Masanori ^a   Kinoshita, Masahiko ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CONGESTIVE HEART FAILURE; CORRELATION FUNCTION; DIAGNOSTIC VALUE; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTEMIC VASCULAR RESISTANCE;

ADOLESCENT; ADULT; AGED; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; BLOOD PRESSURE; ENDOTHELIN-1; FEMALE; FEMORAL ARTERY; FEMORAL VEIN; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; NOREPINEPHRINE; PULMONARY WEDGE PRESSURE; SEVERITY OF ILLNESS INDEX; VASCULAR RESISTANCE;

EID: 0033081635     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00573-7     Document Type: Article

References (32)

1. Yanagisawa M., Kurihara H., Kimura S., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 332:1988;411-415.
2. Stewart D.J., Cernacek P., Costello K.B., Rouleau J.L. Elevated ET-1 in heart failure and loss of normal response to postural change. Circulation. 85:1992;510-517.
3. Cody R.J., Haas G.J., Binkley P.F., Capers Q., Kelley R. Plasma endothelin correlates with extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 85:1992;504-509.
4. Tsutamoto T., Wada A., Maeda Y., Adachi T., Kinoshita M. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol. 23:1994;1427-1433.
5. Yoshibayashi M., Hirata Y., Nakao K., et al. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congestive heart defects evidence of increased production of endothelin in pulmonary hypertension . Circulation. 84:1991;2280-2285.
6. Packer M. Neurohormonal interactions and adaptations in congestive heart failure. Circulation. 77:1988;721-729.
7. Francis G.S., Goldsmith S.R., Levine T.B., Olivary M.T., Cohn J.N. The neurohormonal axis in congestive heart failure. Ann Intern Med. 101:1984;370-377.
8. Cohn J.N., Levine T.B., Olivari M.T., et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 311:1984;819-823.
9. Tsutamoto T., Hisanaga T., Fukai D., et al. Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1 concentration in patients with chronic heart failure. Am J Cardiol. 76:1995;803-808.
10. Yanagisawa M., Inoue A., Ishikawa T., et al. Primary structure, synthesis, and biological activity of rat endothelin, and endothelium-derived vasoconstrictor peptide. Proc Natl Acad Sci USA. 85:1988;6964-6967.
11. Miller W.L., Redfield M.M., Burnett J.C. Jr. Integrated cardiac, renal, and endocrine actions of endothelin. J Clin Invest. 83:1989;317-320.
12. Vierhapper H., Wagner O., Nowotny P., Waldhausl W. Effects of ET-1 in man. Circulation. 81:1990;1415-1418.
13. Lerman A., Hildebrand F.L., Aarhus L.L., Burnett J.C. Endothelin has biological actions at pathophysiological concentrations. Circulation. 83:1991;1808-1814.
14. Kiowski W., Luscher T.F., Linder L., Buhler F.R. Endothelin-1-induced vasoconstriction in humans reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor. Circulation. 83:1991;469-475.
15. Kiowski W., Sutsch G., Hunziker P., et al. Evidence for endothelin-1 mediated vasoconstriction in severe chronic heart failure. Lancet. 346:1995;732-736.
16. Haynes W., Ferro C.J., O'Kane K.P.J., Somerville D., Lomax C.C., Webb D.J. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation. 93:1996;1860-1870.
17. A receptor blockade in chronic heart failure patients with ACE inhibitors. Circulation. 94:1996;2131-2137.
18. for the Bosentan Hypertension Investigators , Krum H., Viskoper R.J., Lacourciere Y., Budde M., Charlon V. The effect of an endothelin-receptor antagonists, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med. 338:1998;784-790.
19. Imai T., Hirata Y., Emori T., Yanagisawa M., Masaki T., Marumo F. Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension. 19:1992;753-757.
20. Kohno M., Yokokawa K., Horio T., Yasunari K., Murakawa K., Takeda T. Atrial and brain natriuretic peptides inhibit the endothelin-1 secretory response to angiotensin II in porcine aorta. Circ Res. 70:1992;241-247.
21. Jilma B., Krejcy K., Dirnberger E., et al. Effects of angiotensin-II infusion at pressor and subpressor doses on endothelin-1 plasma levels in healthy men. Life Sci. 60:1997;1859-1866.
22. Tsutamoto T., Wada A., Maeda K., et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure prognostic role of plasma brain natriuretic peptide in patients with chronic symptomatic left ventricular dysfunction. Circulation. 96:1997;509-516.
23. McMurray J.J., Ray S.G., Abdullah I., Dargie H.J., Morton J. Plasma endothelin in chronic heart failure. Circulation. 85:1992;1374-1379.
24. Dupis J., Stewart D.J., Cernacek P., Gosselin G. Human pulmonary circulation is an important site for both clearance and production of endothelin-1. Circulation. 94:1996;1578-1584.
25. Clavell A.L., Mattingly M.T., Stevens T.L., et al. Angiotensin-converting enzyme inhibition modulates endogenous endothelin in chronic canine thoracic inferior vena caval constriction. J Clin Invest. 97:1996;1286-1292.
26. Hatakeyama H., Miyamori I., Yamagishi S., Takeda Y., Takeda R., Yamamoto H. Angiotensin II up-regulates the expression of type A endothelin receptor in human vascular smooth muscle cells. Biochem Mol Biol Int. 34:1994;127-134.
27. Schiffrin E.L., Deng L.Y., Sventek P., Day R. Enhanced expression of endothelin-1 gene in resistance arteries in severe human essential hypertension. J Hypertens. 15:1997;57-63.
28. Sakai S., Miyauchi T., Kobayashi M., Yamaguchi I., Goto K., Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature. 384:1996;353-355.
29. Tsutamoto T., Kanamori T., Morigami N., Sugimoto Y., Yamaoka O., Kinoshita M. Possibility of downregulation of atrial natriuretic peptide receptor coupled to guanylate cyclase in peripheral vascular beds of patients with chronic severe heart failure. Circulation. 87:1993;70-75.
30. Krum H., Goldsmith R., Wilshire-Clement M., Miller M., Packer M. Importance of endothelin in exercise intolerance of heart failure. Am J Cardiol. 75:1995;1282-1283.
31. Krum H., Gu A., Wilshire-Clement M., et al. Changes in plasma endothelin-1 levels reflect clinical response to β-blocker in chronic heart failure. Am Heart J. 131:1996;337-341.
32. for the U.S. Carvedilol Heart Failure Study Group , Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 334:1996;1349-1355.